 Home > Active Ingredient News > Blood System > J Clin Oncol: Venetoclax+Darelimumab+Dexamethasone±Bortezomib can effectively treat relapsed/refractory multiple myeloma!

J Clin Oncol: Venetoclax+Darelimumab+Dexamethasone±Bortezomib can effectively treat relapsed/refractory multiple myeloma!

 Last Update: 2021-08-26
 Source: Internet
 Author: User

Tags

bright way group

research study articles

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Venetoclax is an oral BCL-2 inhibitor that has single-agent activity for patients with relapsed or refractory multiple myeloma (RRMM) with t(11;14) translocation
.

In addition, it can be used in combination with drugs such as bortezomib, dexamethasone, and daratumumab to enhance the efficacy of Venetog in RRMM

Venetoclax (Weinaituoke) is an orally BCL-2 inhibitor, on T with; translocation relapsed or refractory multiple myeloma (RRMM) patients with single agent activity (14.

This phase 1 study (NCT03314181) evaluated the use of venetork combined with daratumumab and dexamethasone (VenDd) in RRMM patients with t(11;14) translocation, and VenDd+bortezomib (VenDVd) in The efficacy of cytogenetic unselected RRMM patients
.

The primary endpoints are the dose, safety, and overall response rate of the expansion phase study

Remission rate and MRD negative rate

A total of 48 patients were recruited, 24 patients in each of the VenDd group and the VenDVd group
.

One case of dose-limiting toxicity occurred in the VenDd group (grade 3 febrile neutropenia, 800 mg VenDd)

88% and 71% of patients in the VenDd and VenDVd groups had adverse reactions of grade ≥3, respectively.

PFS and OS of each group

In the VenDVd group, an emergency death (sepsis) occurred as the disease progressed; the VenDd group and the VenDVd group were followed up for a median of 20.
9 months and 20.
4 months, respectively, and no other infection- related deaths occurred
.

The overall response rate in the VenDd group was 96% (all very good or better partial responses [ ≥VGPR ]), and the overall response rate in the VenDVd group was 92% (79%≥VGPR)

Infection overall response rate was 96% VenDd group overall response rate was 96% of Group VenDd overall response rate was 92% of Group VenDVd overall response rate was 92% of Group VenDVd

In summary, RRMM patients treated with VenDd or VenDVd regimens can obtain a deeper and longer-lasting high remission rate
.

The results of this study support the further evaluation of the effect of Venetoque combined with daratumumab in the treatment of RRMM patients (especially with t(11;14) translocation)

RRMM patients treated with VenDd or VenDVd regimen can obtain a deeper and longer lasting high remission rate.

Original source:

Nizar J.

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t (11; 14) in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.